CL

Business profile & competitive position

Colgate-Palmolive Company is classified in the Consumer Defensive sector and the Household & Personal Products industry. Its operations are organized around two main segments: Oral, Personal and Home Care, which includes toothpaste, toothbrushes, soaps, deodorants, skin health products, cleaners and fabric conditioners, and Hill’s Pet Nutrition, which produces specialty dog and cat foods. The company markets these products in over 200 countries and territories through retailers, wholesalers, eCommerce platforms, veterinarians and certain direct-to-consumer channels.

The 2025 sales mix underscores where revenue actually comes from: Oral Care represented 44% of worldwide net sales, Pet Nutrition 23%, Personal Care 17% and Home Care 16%. That concentration in Oral Care gives the company a sizable exposure to a high-frequency, repeat-purchase category, while Hill’s adds exposure to the premium pet-food space. Distribution is highly diversified geographically, but customer concentration exists: Walmart and its affiliates accounted for approximately 11% of 2025 net sales, and no other customer exceeded 10%. As of December 31, 2025, Colgate-Palmolive employed roughly 33,600 people across more than 100 countries, with over 84% of that workforce located outside the United States.

On the margin and return fronts, the latest snapshot shows a 9.7% net margin and a 631.1% return on equity (ROE). The net margin indicates that the company can still extract meaningful profit in categories that are competitive and promotion-heavy. The ROE figure is extraordinarily high; in this industry it typically signals not just brand pricing power but also a leveraged capital structure and a comparatively small equity base, which magnifies the measured return on shareholders’ equity. A beta of 0.32 confirms that the stock historically moves much less than the overall market, consistent with defensive, non-discretionary demand for toothpaste, soap and pet food.

Financial posture

As of the current snapshot, Colgate-Palmolive carries a market capitalization of $74.4 billion and trades at a trailing P/E ratio of 36.7. That multiple sits at a premium end of the consumer-staples range and implies that investors are pricing in durable earnings, dividend continuity, or above-average growth in areas such as pet nutrition and premium oral care. The 9.7% net margin and the company’s 631.1% ROE reinforce a narrative of capital efficiency, though the ROE number should be read alongside the balance-sheet structure rather than as a pure operating metric.

The stock’s current price is $93.39, above the 50-day exponential moving average of $89.17. The relative strength index (RSI) is 68.8, which is near the conventional overbought threshold but has not crossed it yet. With a beta of 0.32, the name has historically delivered lower volatility than the broader market, a feature that often attracts income-oriented or defensive positioning. None of these figures, alone or together, amount to a buy or sell signal; they simply describe a high-quality consumer franchise that the market is currently pricing at a meaningful premium to earnings.

Strategic priorities & outlook

The company’s most recent 10-K filing outlines a clear set of operational priorities. Colgate-Palmolive intends to drive organic sales growth and deliver consistent, compounded earnings-per-share growth over time. Operational efficiency is a parallel objective: the company is focused on improving free cash flow and using its balance sheet efficiently, even as it invests behind the business. Brand reach, science-based innovation, an agile supply chain and best-in-class omni-channel demand generation are identified as the tools for achieving that growth and efficiency.

Beyond products and margins, the 10-K also calls out capability building in data, analytics and artificial intelligence, alongside the development of an inclusive corporate culture. These priorities align with the industry-wide push to use AI in demand forecasting, personalized marketing and supply-chain optimization. The sales mix described above— Oral Care at 44% and Pet Nutrition at 23%—gives management two large levers for both innovation and pricing.

Macro & geopolitical exposure

As a Household & Personal Products company doing business in more than 200 countries, Colgate-Palmolive is structurally exposed to several macro and geopolitical factors. Raw-material inputs are central: surfactants, petrochemical-derived packaging, palm oil derivatives, fragrances, resins and energy can all move with commodity prices and freight markets. Any broad increase in these input costs can pressure gross margins unless the company can pass them through via pricing or mix improvements.

Currency exposure is also material. With over 84% of employees located outside the United States and the majority of sales generated internationally, exchange-rate swings can meaningfully affect translated revenue and earnings. Trade policy, tariffs and regional regulations on product formulations, sustainability standards, advertising claims and pet-food ingredients add another layer of complexity. Emerging-market demand is a long-term growth driver for many staples companies, but it also exposes results to local inflation, purchasing-power volatility and political risk. These are sector-level dynamics rather than company-specific predictions, yet they are the backdrop against which Colgate-Palmolive reports quarterly results.

Recent developments

The most recent news flow dated October 19, 2026 is light on directly Colgate-Palmolive-specific headlines but sits within the broader consumer-defensive conversation. Two 247wallst.com pieces—“5 Dividend Stocks for Investors Who Want Income Without the Market's Wild Swings” and “$11,033 in Annual Dividends: What You Keep in a Roth IRA vs. a Taxable Account”—reflect the market’s ongoing appetite for low-beta, dividend-paying consumer staples. Meanwhile, zacks.com coverage of Procter & Gamble's innovation push and Newell Brands' broad-based sales recovery highlight the industrywide themes of innovation-led growth and post-turnaround sales stabilization. None of these articles represent Colgate-Palmolive-specific news, but they illustrate the sector context in which the stock is currently trading.

Earnings behavior & post-earnings drift

Colgate-Palmolive has delivered a remarkably consistent earnings record. Over the last eight reported quarters, the company has beaten consensus earnings estimates every time, for a beat rate of 8/8, or 100%. The average earnings surprise across those eight quarters is 3.3%. In the five trading days following each report, the stock has shown an average upward move of 2.32%, which the data classifies as an “up” post-earnings drift.

The most recent four quarters reinforce that pattern even though the next-day reactions have been mixed:

• July 31, 2026: reported EPS of $0.99 versus an estimate of $0.947, a 4.5% surprise. The stock fell 1.56% the next day but rose 2.16% over the following five sessions.
• May 1, 2026: reported EPS of $0.97 versus an estimate of $0.943, a 2.9% surprise. The stock dropped 2.17% the next day and edged up 0.33% over the next five sessions.
• January 30, 2026: reported EPS of $0.95 versus an estimate of $0.912, a 4.2% surprise. The stock gained 1.77% the next day and climbed 4.56% over the following five sessions.
• October 31, 2025: reported EPS of $0.91 versus an estimate of $0.889, a 2.4% surprise. The stock fell 2.69% on the first day but recovered 2.22% over the subsequent five trading days.

Looking ahead, Colgate-Palmolive is scheduled to report earnings on October 30, 2026, before the market open, with a current consensus EPS estimate of $0.926. The stock is trading at $93.39 with an RSI of 68.8, so price momentum is elevated heading into the print. History suggests the market usually anticipates a beat, and the five-day drift has tended to be positive, but the next-day reaction has not always followed the same direction.

For a deeper dive into how sell-side institutions are currently weighing Colgate-Palmolive’s valuation, earnings setup, and competitive position ahead of the October 30 report, consider reviewing the full institutional verdict and consensus commentary on the ticker page.